Exciting research grants awarded by Jesse’s Journey
One of NMD4C’s partners, Jesse’s Journey (a Canadian charity dedicated to funding research on Duchenne muscular dystrophy), recently announced their research grant recipients for 2020.
NMD4C is very excited that two of our investigators were awarded funding!
Dr. Lawrence Korngut is a neurologist and clinical neurophysiologist. Dr. Korngut has been instrumental in the creation of the Canadian Neuromuscular Disease Registry (CNDR), a Canada-wide registry of people diagnosed with a neuromuscular disease. It collects important medical information from patients across the country to improve the understanding of neuromuscular diseases and accelerate the development of new therapies. Currently, over 4500 neuromuscular patients have registered from across Canada. Jesse’s Journey is one of the original funders of the CNDR and will be funding it for its 12th consecutive year.
Dr. Craig Campbell is a pediatric neurologist. Dr. Campbell is the Head of pediatric neurology at the London Health Sciences Centre Children’s Hospital, which is a lead site for myoblast transplantation in boys with Duchenne. Jesse’s Journey will continue its previous funding of this project into 2020. The project is currently under review; stay tuned for further details!
Another of Jesse’s Journey’s research grants for 2020 was exciting for a different reason — it was the first time they awarded $1 million to a single project!
The project is a Canadian clinical trial evaluating vamorolone in children 2-4 years of age prior to the onset of Duchenne, and in adolescents 7-18 years of age already living with Duchenne — an age range often neglected in clinical trials.
Dr. Eric Hoffman and his team at ReveraGen BioPharma have found a way to tweak the chemistry of standard corticosteroids, the current standard of care, and developed a new molecule that retains the anti-inflammatory benefits but loses much of the activity associated with side effects. ReveraGen has successfully completed Phase I and II programs demonstrating that treatment with vamorolone led to improvements of strength and mobility over six months and preserved over 1.5 years of treatment. Importantly, key side effects, such as stunting of growth, were not observed, and the boys grew normally. This data is supportive of vamorolone having the potential to replace corticosteroids as the standard of care treatment for children and young adults with Duchenne.
Read more about this clinical trial HERE.
See more research funded by Jesse’s Journey HERE.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.